Name (Synonyms) | Correlation | |
---|---|---|
drug2660 | VitalConnect Vital Sign Patch Wiki | 0.58 |
drug2876 | lung ultrasound Wiki | 0.58 |
drug469 | COVID-19 antibodies testing Wiki | 0.58 |
drug467 | COVID-19 Swab Wiki | 0.58 |
drug464 | COVID-19 RT-PCR Wiki | 0.33 |
Name (Synonyms) | Correlation | |
---|---|---|
D001145 | Arrhythmias, Cardiac NIH | 1.00 |
D016171 | Torsades de Pointes NIH | 0.58 |
D001919 | Bradycardia NIH | 0.58 |
D054537 | Atrioventricular Block NIH | 0.58 |
D001281 | Atrial Fibrillation NIH | 0.58 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0004757 | Paroxysmal atrial fibrillation HPO | 0.58 |
HP:0001678 | Atrioventricular block HPO | 0.58 |
HP:0001664 | Torsade de pointes HPO | 0.58 |
HP:0001662 | Bradycardia HPO | 0.58 |
There are 3 clinical trials
The objective of the study is to assess the impact of remote cardiac and vital sign monitoring in patients with coronavirus disease (COVID-19) in the outpatient setting.
Description: ac rhythm in patients with COVID-19 infection following treatment/discharge from MSH
Measure: Number of different arrhythmias Time: 7-14 DaysDescription: Temperature of patients with COVID-19 infection following treatment/discharge from MHS
Measure: Temperature Time: 7-14 DaysDescription: Oxygen saturation level in patients with COVID-19 infection following treatment/discharge from MSH
Measure: Oxygen Saturation Time: 7-14 DaysThe objective of the study is to estimate the frequency of cardiac arrhythmias and characterize the mode of death in patients with coronavirus disease (COVID-19). This is a single-center, retrospective/ prospective registry enrolling all COVID-19 positive patients at Mount Sinai Hospital. Patients who have been diagnosed with COVID-19 infection at Mount Sinai Hospital will be included.
Description: To characterize the frequency of cardiac arrhythmias in patients with COVID-19 infection
Measure: Frequency of cardiac arrhythmias Time: 19 MonthsDescription: To characterize the mode of death in patients with COVID-19 infection
Measure: Mode of death Time: 19 MonthsBACKGROUND AND RATIONALE: There is very limited literature available on the arrhythmia occurrence in the context of an infection by the SARS-CoV2 virus. On the other hand, treatment strategies against the SARS-CoV2 virus may carry a risk of QTc prolongation and pro-arrhythmia/sudden death which may be amplified by concomitant use of other QTc-prolonging drugs and/or ion disbalances. COVIDAR is an international initiative to monitor the occurrence of arrhythmic events in the context of the SARS-CoV2 infection, to identify potential modifiable predisposing factors to reduce their incidence and to inform the best arrhythmia management options in this patient population. MAIN OBJECTIVE: To describe the incidence and type of arrhythmic events in the context of the SARS-CoV2 infection. STUDY DESIGN: patient registry (observational). Patients will not undergo any additional investigations. Only data that is generated during routine clinical care will be collected. STUDY POPULATION: Patients admitted to the hospital highly suspected of or with confirmed COVID-19.
Description: Any arrhythmic event occurring in COVID-19 patients during hospital admission: Monomorphic ventricular tachycardia Polymorphic ventricular tachycardia/Torsades de pointes (non-sustained) Ventricular fibrillation AV-block Severe bradycardia, symptomatic and/or requiring treatment New-onset atrial fibrillation Other
Measure: Arrhythmia Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 monthsDescription: Categorical variable collecting the patient's underlying rhythm at baseline, on treatment and in case of arrhythmic adverse events): sinus rhythm, atrial fibrillation/flutter, other
Measure: Electrocardiographic changes - Underlying rhythm Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 monthsDescription: Collected as a categorical (normal, 1st-, 2nd- or 3rd degree AV block) and a continuous (PR duration in ms) at baseline, on treatment and in case of arrhythmic adverse events)
Measure: Electrocardiographic changes - Atrioventricular conduction Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 monthsDescription: Collected as a continuous variable (ms) at baseline, on treatment and in case of arrhythmic adverse events)
Measure: Electrocardiographic changes - QRS duration Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 monthsDescription: Collected as a categorical variable (not present, type 1 or type 2) at baseline, on treatment and in case of arrhythmic adverse events)
Measure: Electrocardiographic changes - presence of Brugada QRS pattern Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 monthsDescription: Collected as a continuous variable (ms) at baseline, on treatment and in case of arrhythmic adverse events)
Measure: Electrocardiographic changes - QTc duration Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 monthsDescription: Kalium, magnesium and calcium collected as continuous variables at baseline, on treatment and in case of arrhythmic adverse events). Will be reported as a categorical variable (presence/absence) of electrolyte misbalance
Measure: Laboratory abnormalities - electrolyte misbalance Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 monthsDescription: Cardiac CK, troponin T and/or troponin I (where available) collected as a continuous variable at baseline, on treatment and in case of arrhythmic adverse events)
Measure: Laboratory abnormalities - cardiac biomarkers Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 monthsDescription: Creatinine clearance at baseline, on treatment and in case of arrhythmic adverse events)
Measure: Laboratory abnormalities - renal function Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 monthsDescription: Liver enzymes collected at at baseline, on treatment and in case of arrhythmic adverse events)
Measure: Laboratory abnormalities - liver function Time: From date of admission until the date of first documented arrhythmic adverse event or date of death from any cause, whichever came first, assessed up to 12 months